These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 5004178

  • 1. Pharmacodynamic aspects of tolbutamide, glibenclamide, glibornuride and glisoxepide. I. Dose response relations and repeated administration in diabetic subjects.
    Haupt E, Köberich W, Beyer J, Schöffling K.
    Diabetologia; 1971 Dec; 7(6):449-54. PubMed ID: 5004178
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Studies on dose-response relationship of various sulfonylurea derivatives of the old and the new generation with further hints to extrapancreatic mechanisms of decreasing blood sugar].
    Haupt E, Köberich W, Cordes U, Beyer J, Schöffling K.
    Arzneimittelforschung; 1972 Dec; 22():Suppl 12A:2203. PubMed ID: 4198968
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Pharmacological comparison between tolbutamide and two second generation hypoglycemic sulfonylureas (glibenclamide and glisoxepide)].
    Loubatières A, Ribes G, Mariani MM, Alric R.
    Acta Diabetol Lat; 1973 Dec; 10(2):261-82. PubMed ID: 4200420
    [No Abstract] [Full Text] [Related]

  • 9. Glibenclamide, a new sulphonylurea: whither oral hypoglycaemic agents?
    Marble A.
    Drugs; 1971 Dec; 1(2):109-15. PubMed ID: 4999930
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Dose-response relationships of tolbutamide and glibenclamide in diabetes mellitus.
    Heine P, Kewitz H, Schnapperelle U.
    Eur J Clin Pharmacol; 1974 Aug 23; 7(5):321-30. PubMed ID: 4213593
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Comparative use of gliquidone and tolbutamide administered intravenously].
    Zilker T, Lüders L, Bottermann P.
    MMW Munch Med Wochenschr; 1975 Sep 05; 117(36):1421-2. PubMed ID: 126376
    [No Abstract] [Full Text] [Related]

  • 17. [Progress in therapy for diabetes mellitus--insulin-secretion inducing oral hypoglycemic agents].
    Nagashima K, Inagaki N.
    Nihon Naika Gakkai Zasshi; 2009 Apr 10; 98(4):737-41. PubMed ID: 19472523
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The potentiating effect of the simultaneous administration of tolbutamide, glibenclamide, and gliclazide on the development of alloxan-induced diabetes in rats.
    Katsumata K, Katsumata Y.
    Horm Metab Res; 1990 Jan 10; 22(1):51-2. PubMed ID: 2106472
    [No Abstract] [Full Text] [Related]

  • 20. [Insulin, glucose and free fatty acids in the serum of healthy and diabetic subjects following solitary oral dose of the sulfonylurea derivative glibornuride].
    Herrlinger H, Dörfler H, Wolfram G, Zöllner N.
    Verh Dtsch Ges Inn Med; 1971 Jan 10; 77():550-2. PubMed ID: 5155895
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.